^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
irinotecan/floxuridine (LY01616)
i
Other names: LY01616, LY010616
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Luye Group
Drug class:
Topoisomerase I inhibitor, Thymidylate synthase inhibitor
Related drugs:
10d
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=78, Enrolling by invitation, Luye Pharma Group Ltd. | Trial completion date: Oct 2023 --> Oct 2024 | Trial primary completion date: Aug 2023 --> Aug 2024
Trial completion date • Trial primary completion date • Metastases
|
irinotecan • irinotecan/floxuridine (LY01616)
12ms
Safety, Tolerability, Pharmacokinetics (PK), and Primary Clinical Efficacy of LY01616 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=78, Enrolling by invitation, Luye Pharma Group Ltd.
New P1/2 trial • Metastases
|
irinotecan • irinotecan/floxuridine (LY01616)
Share via
